1st Quarter - Report

ALTRIA CLIENT SERVICES LLC for ALTRIA CLIENT SERVICES LLC

Firm
Client
Income
—
Expenses
$2,980,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Government Issues GOV

HR 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; all provisions of the bill HR 1996 SAFE Banking Act of 2021; all provisions of the bill HR 3617 MORE Act of 2021; all provisions of the bill HR 5657 Medical Marijuana Research Act; all provisions of the bill HR 5977 States Reform Act; all provisions of the bill S 253 Cannabidiol and Marihuana Research Expansion Act; all provisions of the bill Discussions in support of the establishment of a comprehensive federal regulatory framework for cannabis

LobbyistCovered position, as disclosed
MICHELLE DIMAROB —
JOHN MASON —
PHIL PARK —
TODD WALKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5977 (117th), H.R. 5657 (117th), H.R. 3617 (117th), H.R. 841 (117th), H.R. 1996 (117th)

Taxation/Internal Revenue Code TAX

HR 5376 Build Back Better Act, provisions related to corporate taxation and federal excise taxes on tobacco products Discussions concerning draft legislation to amend corporate tax rates Discussions concerning draft legislation on dividend tax rates Discussions regarding federal excise taxes on tobacco products Discussions concerning amendments to Section 958(b)(4) of the Internal Revenue Code

LobbyistCovered position, as disclosed
ANGELA ARBOLEDA —
CYNTHIA HAYDEN —
JOHN HOEL —
JENNIFER A KANE —
JOHN MASON —
PHIL PARK —
TODD WALKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th)

Tobacco TOB

HR 4356/S 599 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; potential provisions related to tobacco HR 2471 - Consolidated Appropriations Act, 2022; provisions related to providing FDA authority to regulate products containing synthetic nicotine ANPRMS for Docket Nos. FDA-2017-N-6189 and FDA-2017-N-6565 Final Rule on Premarket Tobacco Product Applications and Substantial Equivalence Marketing Authorization Pathways for New Tobacco Products Proposed Rule regarding Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products Implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act Discussions related to tobacco harm reduction Discussions concerning proposals to ban flavored tobacco products

LobbyistCovered position, as disclosed
ANGELA ARBOLEDA —
CYNTHIA HAYDEN —
JOHN HOEL —
JENNIFER A KANE —
JOHN MASON —
PHIL PARK —
TODD WALKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4356 (117th), H.R. 2471 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.